Longitudinal Modeling of Frontal Cognition in APOE ε4 Homozygotes, Heterozygotes, and Noncarriers

Overview

Journal Neurology

Specialty Neurology

Date 2011 Apr 20

PMID 21502596

Citations 54

Authors

R J Caselli

A C Dueck

D E C Locke

C R Hoffman-Snyder

B K Woodruff

S Z Rapcsak

E M Reiman

Affiliations

Soon will be listed here.

Abstract

Background: Fibrillar amyloid deposition preferentially affects the frontal lobes, temporal pole/neocortex, and posterior cingulate by age 65 years in APOE ε4 carriers prior to the diagnosis of mild cognitive impairment (MCI) and Alzheimer disease (AD), but is it impairing frontally mediated neuropsychological performance?

Methods: A total of 71 ε4 homozygotes (HMZ), 194 ε4 heterozygotes (HTZ), and 356 ε4 noncarriers (NC) who did not differ significantly in mean age (56.6 years), years of education (15.6), gender (70% women), or follow-up duration (6.3 years) had neuropsychological testing every 2 years including the Auditory Verbal Learning Test (AVLT) and frontal/executive tasks sensitive to psychomotor speed, working memory, problem solving, and activity. A subset also received the Iowa Gambling Task (IGT). Findings were then tested in a clinical sample of 27 patients with incident MCI and AD.

Results: APOE ε4 carriers had greater acceleration of decline (quadratic effect) than NC on the AVLT (p = 0.04) but not on any frontal test. APOE ε4 HMZ had greater velocity of decline (linear effects) than NC on all mental arithmetic tests: paced auditory serial attention task (PASAT) 3 second (p = 0.01) and 2 second (p = 0.004) versions; and Wechsler Adult Intelligence Scale-Revised arithmetic (p = 0.048). IGT performance did not differ between 12 ε4 HMZ, 27 ε4 HTZ, and 44 NC. Among 27 patients with incident MCI and AD, the PASAT showed progressive decline preceding diagnosis in 50%.

Conclusions: No frontal cognitive effects were as robust as memory decline. APOE ε4 HMZ declined more quickly than NC on mental arithmetic tests related to frontal lobe-mediated working memory ability.

Citing Articles

P300 Latency with Memory Performance: A Promising Biomarker for Preclinical Stages of Alzheimer's Disease.

Mohamed M, Mohamed N, Kim J Biosensors (Basel). 2024; 14(12).

PMID: 39727881 PMC: 11674962. DOI: 10.3390/bios14120616.

The CSF p-tau/β-amyloid 42 ratio correlates with brain structure and fibrillary β-amyloid deposition in cognitively unimpaired individuals at the earliest stages of pre-clinical Alzheimer's disease.

Cacciaglia R, Shekari M, Salvado G, Mila-Aloma M, Falcon C, Sanchez-Benavides G Brain Commun. 2024; 7(1):fcae451.

PMID: 39723106 PMC: 11668178. DOI: 10.1093/braincomms/fcae451.

Effects of obesogenic diet and 17β-estradiol in female mice with 3/3, 3/4, and 4/4 genotypes.

Christensen A, McGill C, Qian W, Pike C Front Aging Neurosci. 2024; 16:1415072.

PMID: 39347015 PMC: 11427389. DOI: 10.3389/fnagi.2024.1415072.

Substance use moderates relationships between apolipoprotein E genotype, hepatitis C, cognition, and depression in Miami Adult Studies on HIV (MASH) participants.

Burke S, Grudzien A, Li T, Garcia S, Martinez S, Jurich E J Neurovirol. 2024; 30(5-6):500-512.

PMID: 39134913 DOI: 10.1007/s13365-024-01225-8.

Role of light walking pace on cognition: Findings from the Maine-Syracuse Longitudinal Study.

Ahmed F, Guenther B, Thompson J, Lagerstrom L, Robbins M Appl Neuropsychol Adult. 2023; :1-15.

PMID: 37402210 PMC: 10764642. DOI: 10.1080/23279095.2023.2228952.

References

Bouras C, Hof P, Giannakopoulos P, Michel J, Morrison J . Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex. 1994; 4(2):138-50. DOI: 10.1093/cercor/4.2.138. View

Morris J, Roe C, Xiong C, Fagan A, Goate A, Holtzman D . APOE predicts amyloid-beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010; 67(1):122-31. PMC: 2830375. DOI: 10.1002/ana.21843. View

Hardy J, Higgins G . Alzheimer's disease: the amyloid cascade hypothesis. Science. 1992; 256(5054):184-5. DOI: 10.1126/science.1566067. View

Wolk D, Dickerson B . Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. Proc Natl Acad Sci U S A. 2010; 107(22):10256-61. PMC: 2890481. DOI: 10.1073/pnas.1001412107. View

Corder E, Saunders A, Strittmatter W, Schmechel D, Gaskell P, Small G . Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993; 261(5123):921-3. DOI: 10.1126/science.8346443. View

Klunk W, Price J, Mathis C, Tsopelas N, Lopresti B, Ziolko S . Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007; 27(23):6174-84. PMC: 3265970. DOI: 10.1523/JNEUROSCI.0730-07.2007. View

Braak H, Braak E . Frequency of stages of Alzheimer-related lesions in different age categories. Neurobiol Aging. 1997; 18(4):351-7. DOI: 10.1016/s0197-4580(97)00056-0. View

Rapoport M, Dawson H, Binder L, Vitek M, Ferreira A . Tau is essential to beta -amyloid-induced neurotoxicity. Proc Natl Acad Sci U S A. 2002; 99(9):6364-9. PMC: 122954. DOI: 10.1073/pnas.092136199. View

Crook R, Hardy J, Duff K . Single-day apolipoprotein E genotyping. J Neurosci Methods. 1994; 53(2):125-7. DOI: 10.1016/0165-0270(94)90168-6. View

10.

Roberson E, Scearce-Levie K, Palop J, Yan F, Cheng I, Wu T . Reducing endogenous tau ameliorates amyloid beta-induced deficits in an Alzheimer's disease mouse model. Science. 2007; 316(5825):750-4. DOI: 10.1126/science.1141736. View

11.

Ittner L, Ke Y, Delerue F, Bi M, Gladbach A, van Eersel J . Dendritic function of tau mediates amyloid-beta toxicity in Alzheimer's disease mouse models. Cell. 2010; 142(3):387-97. DOI: 10.1016/j.cell.2010.06.036. View

12.

Saunders A, Strittmatter W, Schmechel D, Pericak-Vance M, Joo S, Rosi B . Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993; 43(8):1467-72. DOI: 10.1212/wnl.43.8.1467. View

13.

Wu H, Hudry E, Hashimoto T, Kuchibhotla K, Rozkalne A, Fan Z . Amyloid beta induces the morphological neurodegenerative triad of spine loss, dendritic simplification, and neuritic dystrophies through calcineurin activation. J Neurosci. 2010; 30(7):2636-49. PMC: 2841957. DOI: 10.1523/JNEUROSCI.4456-09.2010. View

14.

Bechara A, Damasio H, Tranel D, Damasio A . Deciding advantageously before knowing the advantageous strategy. Science. 1997; 275(5304):1293-5. DOI: 10.1126/science.275.5304.1293. View

15.

Kok E, Haikonen S, Luoto T, Huhtala H, Goebeler S, Haapasalo H . Apolipoprotein E-dependent accumulation of Alzheimer disease-related lesions begins in middle age. Ann Neurol. 2009; 65(6):650-7. DOI: 10.1002/ana.21696. View

16.

Villemagne V, Pike K, Darby D, Maruff P, Savage G, Ng S . Abeta deposits in older non-demented individuals with cognitive decline are indicative of preclinical Alzheimer's disease. Neuropsychologia. 2008; 46(6):1688-97. DOI: 10.1016/j.neuropsychologia.2008.02.008. View

17.

Hyman B, Van Hoesen G, Damasio A, Barnes C . Alzheimer's disease: cell-specific pathology isolates the hippocampal formation. Science. 1984; 225(4667):1168-70. DOI: 10.1126/science.6474172. View

18.

Reiman E, Chen K, Liu X, Bandy D, Yu M, Lee W . Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci U S A. 2009; 106(16):6820-5. PMC: 2665196. DOI: 10.1073/pnas.0900345106. View

19.

Mormino E, Kluth J, Madison C, Rabinovici G, Baker S, Miller B . Episodic memory loss is related to hippocampal-mediated beta-amyloid deposition in elderly subjects. Brain. 2008; 132(Pt 5):1310-23. PMC: 2677792. DOI: 10.1093/brain/awn320. View

20.

Nicoll J, Wilkinson D, Holmes C, Steart P, Markham H, Weller R . Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med. 2003; 9(4):448-52. DOI: 10.1038/nm840. View